The clinical impact of the physiological effects of erythropoietin and erythropoietin-stimulating agents on the incidence of malignancy, thrombosis and hypertension: Beyond anaemia;El impacto clínico de los efectos fisiológicos de la eritropoyetina y de los agentes estimulantes de la eritropoyetina en la incidencia de malignidad, trombosis e hipertensión: Más allá de la anemia

Nefrologia

Volumn 29, Issue 4, 2009, Pages 288-294

  Ortega, L M ^a   Contreras, G ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

Erythropoietic stimulating agent; Erythropoietin; Glycoprotein; Hypertension; Malignancy; Recombinant human erythropoietin; Thrombosis

Indexed keywords

ANTIANEMIC AGENT; ERYTHROPOIETIN;

ANEMIA; HUMAN; HYPERTENSION; PHYSIOLOGY; REVIEW;

ANEMIA; ERYTHROPOIETIN; HEMATINICS; HUMANS; HYPERTENSION;

EID: 70449700382     PISSN: 02116995     EISSN: None     Source Type: Journal    
DOI: 10.3265/NEFROLOGIA.2009.29.4.5282.EN.FULL     Document Type: Review

References (60)

1. Carnot P, Deflandre C. Sur l'activite hemopoietique de serum au cours de la regenation du sang. CR Acad Sci 1906;143:384-6.
2. Bonsdorff E, Jalvisto E. A humoral mechanism in anoxic erythrocytosis. Acta Physiol Scand 1948;XVI:152.
3. Miyake T, Kung CK, Goldwasser E. Purification of human erythropoietin. J Biol Chem 1977;252:5558-64.
4. Fried W, Barone-Varelas J, Barone T, Anagnostou A. Effect of angiotensin infusion on extrarenal erythropoietin production. JLab Clin Med 1982;99:520-25.
5. Vinearls CG, Oliver DO, Pippard MJ, Reid C, Downing MR, Cotes PM. Effect of human erythropoietin derived from recombinant DNA on the anemia of patients maintained by chronic haemodilysis. Lancet 1986;2:1175-8.
6. Drueke TB, Locatelli F, Clyne N, Eckardt KU, Macdougall IC, Tsakiris D, et al. CREATE Investigators: Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 2006;355:2071-84.
7. Singh AK, Szczech L, Tang KL, Barnhart H, Sapp S, Wolfson M; CHOIR Investigators. Correction of anemia with epoietin alfa in chronic kidney disease. N Engl J Med 2006;355:2085-98.
8. FDA Alert. Information for healthcare professionals: erythropoiesis stimulating agents (ESA) {Aranesp [darbepoetin], Epogen [epoetin alfa] and Procrit [epoetin alfa]). Rockville MD: Food and Drug Aministration, March 9, 2007, Available at http://www.fda.gov/cder/drug/InfoSheets/HCP/RHE2007HCP.htm.
9. Wen D, Boissel JP, Showers M, Ruch BC, Bunn HF. Erythropoietin structure-function relationships. Identification of functionally important domains. J Biol Chem 1994;269:22839-46.
10. Davis JM, Arakawa T, Strickland TW, Yphantis DA. Characterization of recombinant human erythropoietin produced in Chinese hamster ovary cells. Biochemistry 1987;26:2633-8.
11. Dordal MS, Wang FF, Goldwasser E. The role of carbohydrate in erythropoietin action. Endocrinology 1985;116:2293-9.
12. Maxwell PH, Ferguson DJ, Nichols LG, et al. Sites of erythropoietin production. Kidney Int 1997;51:393-401.
13. Jelkmann W. Biochemistry and assay of EPO. In: Jelkmann W (ed.). Erythropoietin: Molecular Biology and Clinical use, chap 2. Johnson City, TN: FP Graham Publishing Co.; 2003. p. 35-63.
14. Wide L, Bengtesson C, Birgegard G. Circadian rhythm of erythropoieitin in human serum. Br J Haematol 1989;72:85-9.
15. Jelkmann W. The enigma of the metabolic fate of circulating erythropoietin (EPO) in view of the pharmacokinetics of the recombinant drugs rHuEPO and NESP. Eur J Haematol 2002;69:265-74.
16. Constantinescu SN, Keren T, Socolovsky M, Nam HS, Henis YI, Lodish HF. Ligand-independent oligomerization of cell-surface erythropoietin receptor is mediated by the transmembrane domain. Proc Natl Acad Sci USA 2001;98,4379-89. Abstract.
17. Remy I, Wilson IA, Michnick SW. Erythropoietin receptor activation by a ligand-induced conformation change. Science 1999;283:990-3.
18. Yi T, Zhang J, Miura O, Ihle JN. Hematopoietic cell phosphatase associates with erythropoietin (EPO) receptor after EPO-induced receptor tyrosine phosphorilation: Identification of potential binding sites. Blood 1995;85:87-95.
19. Anagnostou A, Lee ES, Kessimian N, Levinson R, Steiner M. Erythropietin has a mitogenic and positive chemotactic effect on endothelial cells. Proc Natl Acad Sci USA 1990;87:5978-82. Abstract.
20. Bianchi R, Buyukakilii B, Brines M, Savino C, Cavaletti N, Oggioni G, et al. Erythropietin both protects from and reverses experimental diabetic neuropathy. Proc Natl Acad Sci USA 2004;101:823-8. Abstract.
21. Brines M, Grasso G, Fiordaliso F, Sfacteria A, Ghezzi P, Fratelli M, et al. Erythropoietin mediated tissue protection through an erythropoietin and common B-subunit heteroreceptor. Proc Natl Acad Sci USA 2004;101:14907-12. Abstract.
22. Masuda S, Nagao M, Sasaki R. Erythropoietic, neurotropic, and angiogenic functions of erythropoietin production. Int J Hematol 1999;70:1-6.
23. Caro JJ, Salas M, Ward A, Gross G. Anemia as an independent prognostic factor for survival in patients with cancer: a systemic, quantitative review. Cancer 2001:91:2212-21.
24. Hockel M, Schlenger K, Hockel S, et al. Tumor hypoxia in pelvic recurrences of cervical cancer. Int J Cancer 1998;79:365-9.
25. Wright JR, Ung YC, Julian JA, et al. Randomized, double-blind, placebo-controlled trial of erythropoietin in non-small cell lung cancer and disease-related anemia. J Clin Oncol 2007;25:1027-32.
26. Henke M, Laszig R, Rube C, et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomized, double-blind, placebo-controlled trial. Lancet 2003;362:1255-60.
27. Leyland-Jones B, Semiglazov V, Pawlicki M, Pienkowski T, Tjulandin S, Manikhas G, et al. Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: A survival study. J Clin Oncol 2005;23:6960-72.
28. Fechner G, Muller G, Schmidt D, Garbe S, Hauser S, Vaupel P, Muller SC. Evaluation of hypoxia-mediated growth factors in a novel bladder cancer animal model. Anticancer Res 2007;27:4225-31.
29. Berlyne GM, Diskin C, Gonick H, Dobbie J, Prasad A. Trace elements in dialysis patients. ASAIO Trans 1986;32:662-70.
30. Maisonneuve P, Agodoa L, Gellert R, Stewart JH, Buccinati G, Lowenfels AB, et al. Cancer in patients on dialysis for end-stage renal disease: An international collaborative study. Lancet 1999;354:93-9.
31. D'Andrea AD, Zon LI. Erythropoietin receptor. Subunit structure and activation. J Clin Invest 1990;86:681-7.
32. Kahn P, Frykberg L, Brady C, Stanley I, Beug H, Vennstrom B, Graf T. V-erbA cooperates with sarcoma oncogenes in leukemic cell transformation. Cell 1986;45:349-56.
33. Feldman L, Wang Y, Rhim JS, Bhattacharya N, Loda M, Sytkowski AJ. Erythropietin stimulates growth and STAT5 phosphorylation in human prostate epithelial and prostate cancer cells. Prostate 2006;66:135-45.
34. Solar P, Feldman L, Jeong JY, Busingye JR, Sytkowski AJ. Erythropoietin treatment of human ovarian cancer cells results in enhanced signaling and a paclitaxel-resistant phenotype. Int J Cancer 2008;122:281-8.
35. Saintigny P, Besse B, Callard P, Vergnaud AC, Czernichow S, Colombat M, et al. Erythropoietin and erythropoietin receptor coexpression is associated with poor survival in stage I non-small cell lung cancer. Clin Cancer Res 2007;13;4825-31.
36. Eckardt KU, Mollman M, Neumann R, Brunkhorst R, Burger HU, Lonnemann G, Scholz H, et al. Erythropoietin in polycystic kidneys. J Clin Invest 1989;84:1160-6.
37. Philo JS, Aoki KL, Arakawa T, Narhi LO, Wen J. Dimerization of the extracellular domain of the erythropoietin (EPO) receptor by EPO: One high-affinity and one low-affinity interaction. Biochemistry 1996;35:1681-91.
38. Guntupalli K, Soffer O, Baciewicz P. Pulmonary embolism in end stage renal disease. Intensive Care Med 1990;16:405-7.
39. Casserly LF, Reddy SM, Dember LM. Venous thromboembolism in end-stage renal disease. Am J Kidney Dis 2000;36:405-11.
40. Iannuzzelli A, Kasama R. Hypercoagulability in dialysis patients: fact or fiction? Am J Kidney Dis 2001;37:A20. Abstract 38.
41. Tveit DP, Hypolite IO, Hshieh P, et al. Chronic Dialysis patients have a high risk for pulmonary emboli. Am J Kidney Dis 2002;39:1011-7.
42. Corwin HL, Gettinger A, Fabian T, et al. Efficacy and safety of epoetin alfa in critically ill patients. N Engl J Med 2007;357:965-76.
43. Díaz-Ricart M, Etebanell E, Cases A, López-Pedret J, Castillo R, Ordinas A, et al. Eryhropoietin improves signaling through tyrosine phosphorylation in platelets from uremic patients. Thromb Haemost 1999;82:1312-7.
44. Grandaliano G, Teutonico A, Allegretti A, Losappio R, Mancini A, Gesualdo L, et al. The role of hyperparathyroidism, erythropoietin therapy, and CMV infection in the failure of arteriovenous fistula in hemaodialysis. Kidney Int 2003;64:715-9.
45. Diskin CJ, Stokes TJ, Thomas SG, Ravis W, Lock S, Thomas J, et al. An analysis of the effect of routine medications on hemodialysis vascular acces survival. Nephron 1998;78:365-8.
46. Du J, Peng T, Scheidegger KJ, Delafontaine P. Angiotensin II activation of insulin-like growth factor 1 receptor transcription is mediated by tyrosine kinase-dependent redox-sensitive mechanism. Arterioscler Thromb Vasc Biol 1999;19:2119-26.
47. Keung YK, Owen J. Iron deficiency and thrombosis: literature review. Clin Appl Thromb Hemos 2004;10:387-91.
48. Henry DH, Dahl NV, Auerbach M, et al. Intravenous ferric gluconate significantly improves response to epoietin alfa versus oral iron or no iron in anemic patients with cancer receiving chemotherapy. Oncologist 2007;12:231-42.
49. Besarab AA, Bolton WK, Browne JK, et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoietin. N Engl J Med 1998;339:584-90.
50. Mohini R. Clinical efficacy of recombinant human erythropoietin in hemodialysis patients. Semin Nephrol 1989;9(1):16-21.
51. Hilden M, Leth A, Hilden T. High haemoglobin values during medical treatment of hypertension. Br Med J 1948;3:163-5.
52. Williams B, Edmunds ME, Thompson JP, Burton PR, Feehally J, Walls J. Does increasing haemoglobin concentration and haematocrit have a pressor effect in dialysis patients? Nephrol Dial Transplant 1989;4:787-91.
53. Luft FC. Erythropoietin and arterial hypertension.Clin Nephrol 2000:53(1):S61-4.
54. Phrommintikul A, Haas SJ, Elsik M, et al. Mortality and target haemoglobin concentrations in anaemic patients with chronic kidney disease treated with erythropoietin:a meta-analysis. Lancet 2007:369:381-8.
55. Hampl H, Henning L, Rosenberg CH, et al. Effects of optimized heart failure therapy and anemia correction with epoietin B on left ventricular mass in hemodialysis patients. Am J Nephrol 2005:25:211-20.
56. Lee MS, Lee SJ, Lee JY. Prevention of erythropoietin-associated hypertension. Hypertension 2007;50:439-45.
57. Diskin CJ, Stokes TJ, Dansby L, Radcliff L, Carter T. A hypothesis: can erythropoietin administration affect the severity of retinopathy in diabetic patients with renal failure? Am J Med Sci 2007;334:260-4.
58. Watanabe D, Suzuma K, Matsiu S, Kurimoto M, Suzuma I, et al. Erythropoietin as a retinal angiogenic factor in proliferative diabetic nephropathy. N Engl J Med 2005;353:782-92.
59. Chen J, Connor KM, Aderman CM, Smith LE. Erythropoietin deficiency decreases vascular stability in mice. J Clin Invest 2008;118:526-33.
60. Friedman EA, Brown CD, Berman DH. Erythropoietin in diabetic macular edema and renal insufficiency. Am J Kidney Dis 1995;26:202-8.